Trouble Falling Asleep: When to See a Doctor

What Counts as "Trouble Falling Asleep" Clinically?

Not every rough night warrants a doctor visit. The American Academy of Sleep Medicine (AASM) defines chronic insomnia disorder as difficulty initiating sleep, difficulty maintaining sleep, or early-morning awakening occurring at least three nights per week for at least three months, accompanied by clinically significant daytime distress or functional impairment. Sleep-onset insomnia specifically refers to a sleep-onset latency (the time from lights-out to sleep) consistently above 30 minutes.

The 30/3/3 Rule Clinicians Use

A practical framework used in primary care: if you take more than 30 minutes to fall asleep, on 3 or more nights per week, for 3 or more weeks, that pattern meets the working threshold for evaluation. Shorter durations still deserve attention if daytime consequences are severe.

Acute vs. Chronic Insomnia

Acute insomnia lasts less than three months and is usually tied to an identifiable stressor, a new job, grief, illness. It often resolves without treatment. Chronic insomnia, affecting roughly 10% of the adult population, persists beyond three months and carries elevated risk for depression, cardiovascular disease, and metabolic dysfunction if left untreated. The two categories require different management strategies.

Why You Are Having Trouble Falling Asleep: Main Causes

Sleep-onset difficulty rarely has a single cause. A 2019 review in Sleep Medicine Reviews identified hyperarousal, a state of elevated physiologic and cognitive activation, as the central mechanism across most insomnia subtypes. That review found cortisol, heart rate variability, and beta-wave EEG activity to be consistently elevated in patients with chronic insomnia compared with good sleepers.

Psychological and Behavioral Causes

Anxiety and worry are the most common reasons people report lying awake. Racing thoughts, rehearsing the next day, or replaying events keep the cortex in an alert state incompatible with sleep onset. Major depressive disorder also disrupts sleep architecture, though it more often causes early-morning awakening than sleep-onset delay.

Poor sleep hygiene compounds psychological causes: irregular sleep schedules, afternoon caffeine, bright screens within 90 minutes of bed, and using the bedroom for work all contribute. Research published in Behavioral Sleep Medicine showed that stimulus control therapy, restricting bed use to sleep and sex, reduced sleep-onset latency by a mean of 19 minutes at four-week follow-up.

Medical Causes

Several medical conditions directly delay sleep onset:

• Restless legs syndrome (RLS): An urge to move the legs at rest, typically worse in the evening. The AASM clinical practice guideline recommends dopaminergic agents or alpha-2-delta ligands (gabapentin enacarbil, pregabalin) as first-line pharmacotherapy for moderate-to-severe RLS.
• Obstructive sleep apnea (OSA): Counter-intuitively, untreated OSA can delay sleep onset because arousals during early sleep create a cycle of re-initiation. Roughly 29.4 million U.S. Adults have OSA, most undiagnosed.
• Chronic pain: Musculoskeletal pain, neuropathy, and fibromyalgia all raise arousal at night.
• Hyperthyroidism: Excess thyroid hormone raises heart rate and core body temperature, both of which oppose sleep onset.
• GERD: Nocturnal acid reflux causes discomfort that prevents sleep initiation in a subset of patients.

Medication and Substance Causes

Caffeine has a half-life of 5 to 7 hours. A 200 mg dose consumed at 2 pm leaves 100 mg active at 9 pm in most adults. Alcohol may speed sleep onset initially but suppresses REM sleep and causes rebound awakening after 3 to 4 hours. A 2022 meta-analysis in JMIR Mental Health found that even moderate alcohol use (1 to 2 drinks) reduced overall sleep quality by 24%.

Prescription medications that commonly delay sleep include:

• Beta-agonists (albuterol, salmeterol)
• Stimulant ADHD medications (amphetamine salts, methylphenidate)
• Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine and sertraline when taken at night
• Corticosteroids (prednisone, dexamethasone)
• Decongestants containing pseudoephedrine

Hormonal Causes

Estrogen and progesterone both influence sleep architecture. Progesterone has GABAergic properties that promote sleep; its decline during perimenopause removes that effect. A study in Menopause (N=3,302) found that 45.8% of perimenopausal women and 60.4% of postmenopausal women reported frequent sleep disturbances, compared with 31.1% of premenopausal women. Hot flashes, which occur in up to 80% of women during the menopausal transition, directly fragment sleep by raising core body temperature above the threshold needed for sleep maintenance.

Testosterone deficiency in men also correlates with poorer sleep quality, though the evidence is less strong than for estrogen/progesterone. A 2021 review in The Journal of Clinical Endocrinology and Metabolism reported that hypogonadal men had higher rates of insomnia symptoms, and that testosterone replacement therapy modestly improved sleep-onset latency in men with documented deficiency.

When Should You Worry About Trouble Falling Asleep?

Most insomnia is not a medical emergency. Seek same-day or urgent evaluation for these scenarios:

Red-Flag Situations Requiring Prompt Care

1. Chest pain or palpitations at night, could indicate arrhythmia or cardiac disease triggered by sleep disruption or autonomic dysregulation.
2. Witnessed apnea, a bed partner observing you stop breathing warrants urgent sleep study referral, not watchful waiting.
3. New or worsening psychiatric symptoms, insomnia that precedes or accompanies suicidal ideation, mania, or psychosis needs same-day psychiatric assessment.
4. Sudden-onset insomnia after head injury, traumatic brain injury disrupts the circadian system and requires neurologic evaluation.
5. Extreme daytime sleepiness despite adequate time in bed, narcolepsy or idiopathic hypersomnia can masquerade as insomnia if sleep onset is normal at night but non-restorative.

Routine Medical Evaluation Thresholds

Schedule a standard appointment if any of the following apply:

• Difficulty falling asleep at least three nights per week for more than three weeks
• Daytime impairment: fatigue that affects driving, work performance, or interpersonal function
• Self-medicating with alcohol, over-the-counter antihistamines (diphenhydramine), or cannabis
• Insomnia onset coincides with a new medication
• You are perimenopausal or postmenopausal and sleep disruption is new

The Insomnia Severity Index (ISI) is a validated 7-item questionnaire available free online. A score above 14 (out of 28) indicates moderate-to-severe clinical insomnia and warrants professional evaluation.

How Is Trouble Falling Asleep Diagnosed?

Diagnosis is primarily clinical. There is no blood test for insomnia. A physician or sleep specialist will typically complete the following steps.

Clinical History and Sleep Diary

The clinician asks about sleep-onset latency, total time in bed, wake-after-sleep-onset, sleep quality rating, and daytime consequences. A two-week prospective sleep diary, completed each morning, provides more reliable data than retrospective recall alone. The Consensus Sleep Diary is the standard validated format recommended by sleep medicine researchers.

Screening for Secondary Causes

Blood work may include:

• TSH (to rule out thyroid dysfunction)
• Ferritin (low ferritin below 75 ng/mL is associated with RLS)
• Fasting glucose and HbA1c (nocturia from hyperglycemia disrupts sleep)
• Complete blood count (anemia-related fatigue can mimic or co-occur with insomnia)

Hormone panels (estradiol, FSH, total and free testosterone, SHBG) are indicated when the clinical history suggests a hormonal contribution.

Polysomnography

Overnight polysomnography (PSG) is not routinely ordered for insomnia unless OSA, RLS, REM sleep behavior disorder, or periodic limb movement disorder is suspected. The AASM 2017 clinical practice guideline states that PSG should not be the first-line diagnostic test for chronic insomnia disorder.

Wrist Actigraphy

Actigraphy, a wrist-worn device that estimates sleep-wake cycles from movement, provides objective data over one to two weeks in the patient's natural environment. It is particularly useful for detecting circadian rhythm disorders that mimic insomnia, such as delayed sleep-wake phase disorder.

Treatments for Trouble Falling Asleep

Treatment selection depends on duration, severity, comorbidities, and patient preference. The 2017 AASM Clinical Practice Guideline for Chronic Insomnia recommends CBT-I as the first-line treatment for chronic insomnia disorder in adults.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the most effective long-term treatment for chronic insomnia. It combines sleep restriction therapy, stimulus control, relaxation training, sleep hygiene education, and cognitive restructuring.

In a randomized trial published in JAMA Internal Medicine (N=79), CBT-I reduced sleep-onset latency by 54% at post-treatment and maintained that reduction at 6-month follow-up, compared with a 16% reduction in the sleep medication group. That trial also found that 90% of medication users relapsed to baseline after drug discontinuation, versus 22% of CBT-I participants.

Digital CBT-I programs (Sleepio, Somryst) are FDA-cleared and have shown efficacy in trials published in Sleep, making access less dependent on specialist availability.

FDA-Approved Pharmacotherapy

When CBT-I is unavailable or insufficient, these medications have regulatory approval for sleep-onset insomnia:

| Drug | Class | Approved Dose for Sleep Onset | Schedule | |---|---|---|---| | Zolpidem (Ambien) | Z-drug / GABA-A agonist | 5 to 10 mg (women 5 mg) | Immediate-release; C-IV | | Eszopiclone (Lunesta) | Z-drug / GABA-A agonist | 1 to 2 mg | C-IV | | Lemborexant (Dayvigo) | Dual orexin receptor antagonist | 5 to 10 mg | C-IV | | Suvorexant (Belsomra) | Dual orexin receptor antagonist | 10 to 20 mg | C-IV | | Doxepine (Silenor) | TCA / histamine antagonist | 3 to 6 mg | Non-controlled |

The FDA label for zolpidem was revised in 2013 to lower the recommended dose for women to 5 mg after pharmacokinetic data showed higher plasma concentrations in women, increasing next-morning impairment risk.

Orexin receptor antagonists (lemborexant, suvorexant) are preferred in older adults because they carry lower risk for falls and cognitive impairment compared with benzodiazepines and Z-drugs, per the 2023 American Geriatrics Society Beers Criteria.

Hormone Therapy for Perimenopausal Insomnia

For women whose sleep-onset difficulty is driven by hot flashes or the hormonal changes of perimenopause, menopausal hormone therapy (MHT) addresses the root cause rather than the symptom. A Cochrane review of 23 RCTs found that estrogen-based MHT significantly improved self-reported sleep quality and reduced nighttime waking in symptomatic perimenopausal and postmenopausal women.

The Menopause Society (NAMS) 2022 Position Statement states: "For women who are bothered by vasomotor symptoms and are within 10 years of menopause or under age 60 with no contraindications, the benefits of hormone therapy outweigh the risks."

For women with contraindications to estrogen, low-dose paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal treatment for vasomotor symptoms, and it reduces hot-flash-related sleep disruption. Phase III trial data showed a 6-point reduction in hot flash composite score versus 3.9 for placebo (P<0.001).

Sleep Hygiene: What the Evidence Actually Supports

Sleep hygiene alone is insufficient for chronic insomnia. A meta-analysis in Psychological Bulletin (k=60 studies) found that sleep hygiene interventions produced a standardized mean difference of only 0.22 on sleep outcomes when delivered without behavioral components, clinically negligible on its own.

The following specific behaviors have individual-level evidence:

• Consistent wake time: Anchoring the wake time stabilizes the circadian pacemaker within 5 to 7 days.
• Cooler bedroom temperature: Core body temperature must drop 1 to 2 degrees Fahrenheit to initiate sleep. A bedroom temperature between 65°F and 68°F (18°C to 20°C) supports that drop.
• Light exposure: Morning bright light (2,500 lux for 30 minutes within 30 minutes of waking) advances the circadian phase and improves evening sleepiness. A 2019 RCT in SLEEP showed 14-minute earlier sleep onset after 4 weeks of morning light therapy versus dim light control.
• Caffeine cutoff: Stopping caffeine intake by noon reduces sleep-onset latency in caffeine-sensitive individuals, per data from the Sleep Foundation cohort study.

What Does Not Work

Over-the-counter diphenhydramine (ZzzQuil, Unisom SleepTabs, Benadryl) builds tolerance within 4 nights of consecutive use. A pharmacokinetic review found residual sedation 8 hours post-dose in adults over 50, increasing fall risk. Melatonin at standard doses (0.5 mg to 5 mg) shortens sleep-onset latency by a mean of 7 minutes, per a 2013 Cochrane meta-analysis (k=19 RCTs), meaningful only for circadian rhythm disorders, not for primary sleep-onset insomnia.

Special Populations and Considerations

Older Adults

Insomnia prevalence rises to 30 to 48% in adults over 65. Age-related reductions in slow-wave sleep, increased sleep fragmentation, and earlier circadian phase all contribute. The Beers Criteria explicitly lists benzodiazepines and Z-drugs as potentially inappropriate for adults 65 and older. CBT-I retains efficacy in this population with a mean reduction in sleep-onset latency of 22 minutes in trials enrolling adults over 60.

Adolescents

Delayed sleep-wake phase disorder peaks in adolescence, with natural sleep onset shifting to 1 to 3 am biologically. This is not the same as behavioral insomnia. A 2020 statement from the American Academy of Pediatrics recommended that middle and high school start times shift to 8:30 am or later to align with adolescent circadian biology.

Pregnancy

Insomnia affects up to 78% of pregnant women, particularly in the third trimester. Pharmacologic options are severely limited. CBT-I delivered via telehealth showed a 52% remission rate in a 2020 RCT (N=208) in pregnant women, versus 4% in the control arm.

Monitoring and Follow-Up After Starting Treatment

Once treatment begins, reassessment should occur at 4 weeks. The ISI score, sleep diary data, and daytime function all provide outcome measures. For pharmacotherapy, the prescriber should confirm:

• Sleep-onset latency has decreased below 30 minutes on most nights
• Next-day sedation or cognitive impairment is absent
• No dose escalation has occurred (tolerance signal for Z-drugs)

For CBT-I, the initial weeks often feel worse due to sleep restriction protocols. This is expected and resolves by week 3 to 4 in most patients. Communicating this timeline upfront improves adherence.

The AASM recommends that pharmacotherapy for chronic insomnia be used at the lowest effective dose, for the shortest duration necessary, with concurrent CBT-I referral where available. Patients should not discontinue Z-drugs or benzodiazepines abruptly, a tapered withdrawal over 4 to 8 weeks minimizes rebound insomnia.

If first-line CBT-I and single-agent pharmacotherapy fail after 8 weeks, referral to a board-certified sleep medicine physician is appropriate. At that point, evaluation for occult OSA, circadian rhythm disorders, or psychiatric comorbidity may change the diagnosis entirely.